Alkaline Phosphatase, an Unconventional Immune Protein

Bethany A. Rader*

Department of Microbiology, Southern Illinois University, Carbondale, IL, United States

Recent years have seen an increase in the number of studies focusing on alkaline phosphatases (APs), revealing an expanding complexity of function of these enzymes. Of the four human AP (hAP) proteins, most is known about tissue non-specific AP (TNAP) and intestinal AP (IAP). This review highlights current understanding of TNAP and IAP in relation to human health and disease. TNAP plays a role in multiple processes, including bone mineralization, vitamin B6 metabolism, and neurogenesis, is the genetic cause of hypophosphatasia, influences inflammation through regulation of purinergic signaling, and has been implicated in Alzheimer’s disease. IAP regulates fatty acid absorption and has been implicated in the regulation of diet-induced obesity and metabolic syndrome. IAP and TNAP can dephosphorylate bacterial-derived lipopolysaccharide, and IAP has been identified as a potential regulator of the composition of the intestinal microbiome, an evolutionarily conserved function. Endogenous and recombinant bovine APs and recombinant hAPs are currently being explored for their potential as pharmacological agents to treat AP-associated diseases and mitigate multiple sources of inflammation. Continued research on these versatile proteins will undoubtedly provide insight into human pathophysiology, biochemistry, and the human holobiont.

Keywords: alkaline phosphatase, hypophosphatasia, tissue non-specific AP, intestinal AP, lipopolysaccharide, microbiome

INTRODUCTION

Alkaline phosphatases (APs) belong to a superfamily of proteins (EC 3.1.3.1) sharing conservation of metal binding sites, amino acids required for activity, and predicted fold structure (1). APs are used extensively in life sciences education, as a tool in molecular biology research and as a blood serum marker for liver and bone health, and yet we know surprisingly little about the potential these proteins have to influence our health. In general, APs are anchored to outside surface of the plasma membrane and catalyze the hydrolysis of phosphate groups from a variety of different substrates (dephosphorylation) in an alkaline environment, freeing inorganic phosphate (Pi) (2–4). APs are ubiquitous, with members of the AP super family of proteins extending from the archaea (5) to humans (2). Their ubiquity across life and their expansion and subsequent dynamic evolution in vertebrates implies both variety and conservation of function (6, 7). There are four genes encoding APs in humans. Three genes, ALPI, ALPP, and ALPPL2, display tissue-specific expression (TSAP proteins), whereas the fourth, ALPL is tissue non-specific in expression [tissue non-specific AP (TNAP) proteins] (Table 1). Unlike tissue distribution, surprisingly less is known about the function of these proteins, especially ALPP and ALPPL2 (Table 1). This mini-review will briefly highlight current knowledge of TNAP and intestinal AP (IAP) function in human health and disease (see Figure 1 for summary).
TISSUE NON-SPECIFIC AP

The most direct link between APs and human disease is hypophosphatasia (HPP), a disease characterized by mutations in TNAP associated with decreased enzyme activity in specific organs \( (10, 11) \) (Figure 1B). This decrease in AP activity results in variable symptoms that range from perinatal HPP that can result in still birth from profound skeletal hypomineralization \( (11, 12) \), potentially lethal seizures in infantile HPP \( (13–15) \), to milder phenotypes such as bone fractures and periodontal disease in juvenile HPP and adult HPP \( (16, 17) \). A relatively recent mouse model for HPP, in conjunction with medical data and genetic analysis has provided insight into the mechanism of HPP pathophysiology regarding at least two TNAP substrates, extracellular pyrophosphate (PPI), and pyridoxal-5-phosphate (PLP) \( (7) \).

HYPOPHOSPHATASIA

Tissue non-specific AP is anchored to the cell membranes of osteoblasts and chondrocytes and to matrix vesicles released by those cells, where it degrades PPI to Pi. PPI is an inhibitor of mineralization \( (18) \) and regulation by TNAP controls propagation of extracellular mineralization of apatite crystals. TNAP deficiency increases the amount of inhibitory PPI thus decreasing extracellular mineralization, and humans with HPP show a loss of mineralization fronts \( (19) \). This has been recapitulated in a TNAP knockout mouse model for infantile HPP \( (20–22) \). The loss of mineralization results in various symptoms including softening of bone, bowing and spontaneous breakage of bones, rickets, and tooth (dentin/cementum/enamel) defects \( (23) \).

**TABLE 1** | Description of human alkaline phosphatases (APs).a

| AP gene | AP protein | Tissue distribution | Known function |
|---------|------------|---------------------|----------------|
| ALPL    | Tissue non-specific AP | Liver, kidney, skeletal tissue, nervous system | Bone and tooth deposition |
| ALPP    | PLAP Δ | Syncytiotrophoblasts, reproductive tumors | Unknown |
| ALPPL2  | GCAP Δ | Testis, reproductive tumors | Unknown |
| ALPI    | IAP Δ | Intestine, enterocyte | Fatty acid absorption, lipopolysaccharide detoxification |

*aInformation from Ref. \( (2, 7) \).

ΔTSAPs.

**FIGURE 1** | Summary of human APs (hAPs) tissue non-specific AP (TNAP) and intestinal AP (IAP). **(A)** Established and proposed functions of TNAP and IAP. **(B)** Disease states in which increase, decrease, or dysregulation of hAPs is either indicative or causative. Background image modified from the tertiary structure of human PLAP generated by http://www.rcsb.org/pdb (PDB ID: 3MK2) \( (8) \).
Pyridoxal-5-phosphate, the active form of vitamin B6 (24), is elevated in the serum of HPP patients (25, 26). Hydrolysis of PLP to pyridoxal (PL) by TNAP facilitates diffusion of PL across cell membranes, where it is then re-phosphorylated into PLP. PLP is a versatile cofactor for an estimated 4% of enzymatic reactions and is used by over 110 enzymes to produce or metabolize various molecules (27). PLP-dependent enzymes in the brain are responsible for the production of important neurochemicals including serotonin, dopamine, and gamma-aminobutyric acid (28). The decrease in PLP and resulting decrease in PLP-dependent metabolism in the brain in perinatal HPP patients has been implicated as the cause of neonatal seizures (29, 30).

NON-HPP TNAP PATHOPHYSIOLOGY

Tissue non-specific AP has been implicated in non-HPP related medical conditions (Figure 1B). TNAP is expressed during embryonic neural and spinal chord development, and promotes axonal growth in vitro and neurogenesis in adults (31), suggesting an importance in proper neural function. Indeed, increased TNAP activity in the brain has been demonstrated in postmortem hippocampus and serum samples from Alzheimer’s disease patients and has been implicated in neuronal death through increased dephosphorylation of tau (32). Increased serum levels of AP (TNAP and/or TSAPs) due to mutations in GPI anchor synthesis, termed hyperphosphatasia, results most notably in Marby syndrome characterized by seizures, intellectual disability, and facial dysmorphology (33). TNAP upregulation in the vasculature contributes to medial vascular calcification causing vascular stiffening and eventually heart failure (34, 35).

An emerging function for TNAP is regulation of purinergic signaling. Extracellular ATP and ADP, through the binding of nucleotide receptors, act as signals inducing inflammation after an acute event such as necrosis induced by damage or infection that releases intracellular nucleotides. In contrast, degradation of extracellular ATP and ADP to AMP and adenosine causes cessation of inflammatory signaling, and induction through adenosine receptors of an anti-inflammation response (36, 37). TNAP has been implicated in protection against inflammation in multiple diseases and promotion of intestinal microbial populations through hydrolysis of extracellular ATP/ADP to AMP and adenosine (38–40).

INTESTINAL AP

Intestinal AP is expressed in villus-associated enterocytes where it regulates fatty acid absorption through secretion of vesicles at both the luminal and basolateral surfaces (41, 42), regulates bicarbonate secretion and duodenal surface pH (43), and has been implicated in the regulation of diet-induced obesity (44, 45) and metabolic syndrome (46, 47) (Figure 1A). But perhaps, the most remarkable function of IAP centers on its protective interactions with the bacterial symbionts that inhabit or invade our enteric system. IAP has been shown to dephosphorylate (detoxify) the lipid A moiety of lipopolysaccharide (LPS), the outer lipid layer of the outer membrane of Gram-negative bacteria (48). In vertebrates, these phosphates are important for binding of LPS to the toll-like receptor 4/MD-2 innate immune receptor complex (49), initiation of NF-kB signaling, and immune response induction (50–52).

Intestinal AP deficiency has been associated with inflammation in the human intestine (53) and in the intestines of vertebrate models in which AP levels are decreased (54). Supplementation of IAP to animals where intestinal inflammation is induced directly or indirectly (with antibiotic use for example) reduces inflammation (53, 55, 56). In addition, a protective role has been ascribed to IAP in mouse models of necrotizing enterocolitis (57–59). This protective role may include IAP-dependent shaping (60) and homeostasis (61) of the microbiome. Along with direct regulation of intestinal homeostasis, IAPs and LPS detoxification have been implicated in other immune-related processes including prevention of bacterial translocation by endogenous or pharmacologically administered IAPs (62–64), and resolution of intestinal inflammation and tissue regeneration (65–67). It should also be noted that in addition to vertebrate IAP, TNAP has been shown to dephosphorylate LPS when it is applied to tissue sections from rat livers (68) and in the mouse uterus (69). With the current and increasing interest in the microbiome, IAP function as it relates to interaction with the endogenous microbes and its influence on human health will undoubtedly be clarified in the coming years.

CLINICAL USE OF APs

Although there are a multitude of AP studies focusing on vertebrate models of disease, there are relatively few publications to date reporting pharmacological use of APs as a treatment in humans. At the time this article was written, a search of http://clinicaltrials.gov using AP as a search term produced over several hundred responses, however, the vast majority assay for AP levels in serum (a constant hazard when searching any science or medical database using “alkaline phosphatase” as a search term). However, there were at least 11 clinical trials concerning AP treatment of HPP, 3 concerning AP treatment of sepsis with renal injury or failure, 2 concerning AP treatment during or after cardiac surgery, and at least 1 each concerning AP treatment of rheumatoid arthritis, and ulcerative colitis (UC). Interestingly, these studies use several AP sources such as isolated bovine IAP (bIAP), recombinant bIAP, and recombinant human Aps (hAPs). AP enzyme replacement therapy is also currently available to treat HPP. A recombinant soluble human TNAP has been approved for use in perinatal, infantile, and juvenile-onset HPP (70, 71) and has proven successful in symptom improvement and survival in perinatal and infantile HPP (72, 73). In addition to HPP, use of AP as treatment increased renal function in sepsis-induced acute kidney injury (74, 75) and showed short-term improvement of severity of UC in patients with moderate-to-severe UC (76). These studies are a first glimpse into AP use as a treatment for disease, with very positive results. Given the jack of all trades nature of APs and the potential for APs as pharmacological agents in various diseases, studies like these should increase in the coming years.
**REFERENCES**

1. Galperin MV, Koonin EV, Bairoch A. A superfamily of metalloenzymes unifies phosphopentomutase and cofactor-independent phosphoglycerate mutase with alkaline phosphatases and sulfatases. *Protein Sci* (1998) 7:1829–35. doi:10.1002/pro.5560070819

2. Millán JL. *Mammalian Alkaline Phosphatases: From Biology to Applications in Medicine and Biotechnology*. Weinheim: Wiley-VCH (2006).

3. Lalles JP. Intestinal alkaline phosphatase: multiple biological roles in maintenance of intestinal homeostasis and modulation by diet. *Nutr Rev* (2010) 68:323–32. doi:10.1111/j.1753-4887.2010.00292.x

4. Lalles JP. Intestinal alkaline phosphatase: novel functions and protective effects. *Nutr Rev* (2014) 72:82–94. doi:10.1111/nure.12082

5. Zimmerman AE, Martiny AC, Allison SD. Microdiversity of extracellular enzyme genes among sequenced prokaryotic genomes. *ISME J* (2013) 7:1187–99. doi:10.1038/ismej.2012.176

6. Yang Y, Wandler AM, Postlethwait JH, Guillemín K. Dynamic evolution of the LPS-detoxifying enzyme intestinal alkaline phosphatase in zebrafish and other vertebrates. *Front Immunol* (2012) 3:314. doi:10.3389/fimmu.2012.00314

7. Buchet R, Millán JL, Magne D. Multisystemic functions of alkaline phosphatases. *Methods Mol Biol* (2013) 1053:27–51. doi:10.1007/978-1-62703-562-0_3

8. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein databank. *Nucleic Acids Res* (2000) 28:235–42. doi:10.1093/nar/28.1.235

9. Stec B, Cheltsov A, Millán JL. Refined structures of placental alkaline phosphatase show a consistent pattern of interactions at the peripheral site. *Acta Crystallogr Sect F Struct Biol Cryst Commun* (2010) 66:866–70. doi:10.1107/S1744309110019767

10. Lingart A, Biosse-Duplan M. Hypophosphatasia. *Curr Osteoporos Rep* (2016) 14:95–105. doi:10.1007/s11914-016-0309-0

11. Mornet E. Hypophosphatasia: the mutations in the tissue-nonspecific alkaline phosphatase gene. *Hum Mutat* (2000) 15:309–15. doi:10.1002/(SICI)1098-1004(200004)15:4<309::AID-HUMU2>3.0.CO;2-C

12. Olech EM, Zemotjel S, Sowińska-Seidler A, Robinson PN, Mundlos S, Karczewski M, et al. Identification of a molecular defect in a stillborn fetus with perinatal lethal hypophosphatasia using a disease-associated genome sequencing approach. *Pol J Pathol* (2016) 67:78–83. doi:10.5114/pjp.2016.59480

13. Baumgartner-Sigl S, Haberlandt E, Mumm S, Scholl-Bürgi S, Sergi C, Ryan L, et al. Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T > C, p.M226T; c.1112C > T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. *Bone* (2007) 40:1655–61. doi:10.1016/j.bone.2007.01.020

14. Nunes ML, Mugnol F, Bica I, Fiori RM. Pyridoxine-dependent seizures associated with hypophosphatasia in a newborn. *J Child Neurol* (2002) 17:222–4. doi:10.1177/08830370201700314

15. De Roo MG, Abeling NG, Majoe CB, Bosch AM, Koelman JH, Clobben JM, et al. Infantile hypophosphatasia without bone deformities presenting with severe pyridoxine-resistant seizures. *Mol Genet Metab* (2014) 111:404–7. doi:10.1016/j.ymgen.2013.09.014

16. Moulin P, Vaysse F, Bieth E, Mornet E, Gennero I, Dalicieux-Laurencin S, et al. Hypophosphatasia may lead to bone fragility: don’t miss it. *Eur J Pediatr* (2009) 168:783–8. doi:10.1007/s00431-008-0835-6

17. Weber TJ, Sawyer EK, Moseley S, O’Donjén T, Kishnani PS. Burden of disease in adult patients with hypophosphatasia: results from patient-reported outcome surveys. *Metabolism* (2014) 63:1522–30. doi:10.1016/j.metabol.2016.07.006

18. Fleisch H, Bisaz S. Mechanism of calcification: inhibitory role of pyrophosphate. *Nature* (1962) 195:911. doi:10.1038/195911a0

19. Anderson HC, Hsu HH, Morris DC, Fedde KN, Whyte MP. Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals. *Am J Pathol* (1997) 151:1555–61.

20. Goldberg RF, Austen WG, Zhang X, Munene G, Mostafa S, Biswas S, et al. Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. *Proc Natl Acad Sci U S A* (2008) 105:3551–6. doi:10.1073/pnas.0712140105

21. Fedde KN, Blair L, Silverstein J, Coburn SP, Ryan LM, Weinstein RS, et al. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. *J Bone Miner Res* (1999) 14:2015–26. doi:10.1359/jbmr.1999.14.12.2015

22. Millán JL, Yadav M, Simao A, Narisawa S, Huesa C, McKeever MD, et al. Loss of bone mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function. *Bone* (2010) 46:578. doi:10.1016/j.bone.2010.01.191

23. Millán JL. The role of phosphatases in the initiation of skeletal mineralization. *Calciif Tissue Int* (2013) 93:299–306. doi:10.1007/s00223-012-9672-8

24. Shideler CE. Vitamin B6: an overview. *Am J Med Technol* (1983) 49:17–22.

25. Whyte MP, Mahuren JD, Vrabel LA, Coburn SP. Markedly increased circulating pyridoxal-5’-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism. *J Clin Invest* (1983) 72:752–6. doi:10.1172/JCI112031

26. Whyte MP, Mahuren JD, Fedde KN, Cole FS, McCabe ERB, Coburn SP. Perinatal hypophosphatasia: tissue levels of vitamin B6 are unremarkable despite markedly increased circulating concentrations of pyridoxal-5’-phosphate. Evidence for an ectoenzyme role for tissue-nonspecific alkaline phosphatase. *J Clin Invest* (1988) 81:1234–9. doi:10.1172/JCI113440

27. Percudani R, Peracchi A. The B6 database: a tool for the description and classification of vitamin B6-dependent enzymatic activities and of the corresponding protein families. *BMC Bioinformatics* (2009) 10:273. doi:10.1186/1471-2105-10-273

28. Cruz T, Gleizes M, Balayssac S, Mornet E, Marsal G, Millán JL, et al. Identification of altered brain metabolites associated with TNAP activity in a mouse model of hypophosphatasia using untargeted NMR-based metabolomics analysis. *J Neurochem* (2017) 140:919–40. doi:10.1111/jnc.13950

**AUTHOR CONTRIBUTIONS**

BR solely contributed to the production of this manuscript.

**ACKNOWLEDGMENT**

This work was supported by NIH grant 1R15GM119100 to BR.
42. McConnell RE, Higginbotham JN, Shifrin DA, Tabb DL, Coffey RJ, Šefčíková Z, Hájek T, Lenhardt L, Racek L, Mozes S. Different functional aspects of high-density lipoprotein metabolism in mononuclear cells from healthy and at-risk individuals. *Hum Mol Genet* (2016) 1–14. doi:10.1093/hmg/ddv248

43. Akiba Y, Mizumori M, Guth PH, Engel E, Kaunitz JD. Duodenal brush border alkaline phosphatase in the developing brain and in adult neurogenesis. *Subcell Biochem* (2015) 75:61–84. doi:10.1007/978-94-017-7197-9_17

44. Kellett KAB, Hooper NM. The role of tissue non-specific alkaline phosphatase in colorectal cancer. *Adv Exp Med Biol* (2009) 652:281–93. doi:10.1007/978-1-4419-0637-7_6

45. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of TLR4. *Nat Rev Immunol* (2003) 3:169–76. doi:10.1038/nri1004

46. Malo MS, Moaven O, Muhammad N, Biswas B, Alam SN, Economopoulos KP, et al. Intestinal alkaline phosphatase inhibits the translocation of bacteria of gut-origin in mice with experimental colitis. *J Surg Res* (2017) 218:35–42. doi:10.1016/j.jss.2017.03.049

47. Cauwels A, Rogge E, Vandendriessche B, Shiva S, Brouckaert P. Extracellular adenosine production after infant cardiopulmonary bypass. *PLoS One* (2016) 11:e0158981. doi:10.1371/journal.pone.0158981

48. Kaliannan K, Hamarneh SR, Economopoulos KP, Nasrin Alam S, Moaven O, Patil P, et al. Intestinal alkaline phosphatase prevents metabolic syndrome in mice. *Proc Natl Acad Sci U S A* (2013) 110:7003–8. doi:10.1073/pnas.1220180110

49. Bentila H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Neijer DKF, Poelstra K. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. *Shock* (2002) 18:561–6. doi:10.1097/01.shk.0000043623.17707.47

50. Park BS, Song DH, Kim HM, Choi B-S, Lee H, Lee J-O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. *Nature* (2009) 458:1191–5. doi:10.1038/nature07830

51. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. *J Immunol* (1999) 162:3749–52. doi:10.4049/jimmunol.162.11.3749

52. Akira S, Yamamoto M, Lipid a receptor TLR4-mediated signaling pathways. *Adv Exp Med Biol* (2009) 667:59–68. doi:10.1007/978-1-4419-1603-7_6

53. Rentea RM, Liedel JL, Welak SR, Cassidy LD, Mayer AN, Pritchard KA, et al. Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis. *Inflamm Bowel Dis* (2011) 17:532–42. doi:10.1002.ibd.21377

54. Alam SN, Yamine H, Moaven O, Ahmed R, Moss AK, Biswas B, et al. Intestinal alkaline phosphatase prevents antibiotic-induced susceptibility to enteric pathogens. *Annu Surg* (2014) 259:715–22. doi:10.1097/SLA.0b013e31828f4e14

55. Heinzerling NP, Liedel JL, Velak SR, Fredrich K, Biesterveld BE, Pritchard KA, et al. Intestinal alkaline phosphatase is protective to the preterm rat pup intestine. *J Pediatr Surg* (2014) 49:954–60. doi:10.1016/j.jpedsurg.2014.01.031

56. Rentea RM, Liedel JL, Velak SR, Cassidy LD, Mayer AN, Pritchard KA, et al. Intestinal alkaline phosphatase administration in newborns is protective of gut barrier function in a neonatal necrotizing enterocolitis rat model. *J Pediatr Surg* (2012) 47(6):1135–41. doi:10.1016/j.jpedsurg.2012.03.018

57. Biesterveld BE, Koehler SM, Heinzerling NP, Rentea RM, Fredrich K, Velak SR, et al. Intestinal alkaline phosphatase to treat necrotizing enterocolitis. *J Surg Res* (2015) 196:335–40. doi:10.1016/j.jss.2015.02.030

58. Fawley J, Koehler S, Cabrera S, Lam V, Fredrich K, Hessner M, et al. Intestinal alkaline phosphatase deficiency leads to dysbiosis and bacterial translocation in the newborn intestine. *J Surg Res* (2017) 218:35–42. doi:10.1016/j.jss.2017.03.049

59. Malo MS, Alam SN, Mostafa G, Zeller SJ, Johnson PV, Mohammad N, et al. Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. *Gut* (2010) 59:1476–84. doi:10.1136/gut.2010.211706

60. Shifrin DA, McNicholl RE, Nambiar R, Higginbotham JN, Coffey RJ, et al. Enterocyte microvillus-derived vesicles detoxify bacterial products and regulate epithelial-microbial interactions. *Curr Biol* (2007) 17:532–42. doi:10.1016/j.cub.2007.01.022

61. Martinez-Moya P, Ortega-González M, González R, Anzola A, Ocón B, et al. Effect of glutamine-enriched, elemental diet on regeneration of residual small bowel mucosa and hepatic steatosis following massive bowel resection. *J Clin Biochem Nutr* (1993) 15:219–25. doi:10.3164/jcbn.15.219
66. Campbell EL, Macmanus CF, Kominsky DJ, Keely S, Glover LE, Bowers BE, et al. Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. *Proc Natl Acad Sci U S A* (2010) 107:14303. doi:10.1073/pnas.0914730107

67. Liu W, Hu D, Huo H, Zhang W, Adilaghdam F, Morrison S, et al. Intestinal alkaline phosphatase regulates tight junction protein levels. *J Am Coll Surg* (2016) 222:1009–17. doi:10.1016/j.jamcollsurg.2015.12.006

68. Poelstra K, Bakker WW, Klok PA, Kamps JA, Hardonk MJ, Meijer DK. Dephosphorylation of endotoxin by alkaline phosphatase in vivo. *Am J Pathol* (1997) 151:1163–9.

69. Lei W, Ni H, Herrington J, Reese J, Paria BC. Alkaline phosphatase protects lipopolysaccharide-induced early pregnancy defects in mice. *PLoS One* (2015) 10:e0123243. doi:10.1371/journal.pone.0123243

70. Bloch-Zupan A. Hypophosphatasia: diagnosis and clinical signs – a dental surgeon perspective. *Int J Paediatr Dent* (2016) 26(6):426–38. doi:10.1111/ipd.12232

71. Orimo H. Pathophysiology of hypophosphatasia and the potential role of asfotase alfa. *Ther Clin Risk Manag* (2016) 12:777–86. doi:10.2147/TCRM.S87956

72. Whyte MP, Rockman-Greenberg C, Ozono K, Riese R, Moseley S, Melian A, et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. *J Clin Endocrinol Metab* (2016) 101:334–42. doi:10.1210/jc.2015-3462

73. Hofmann C, Seefried L, Jakob F. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia. *Drugs Today (Barc)* (2016) 52:271–85. doi:10.1358/dot.2016.52.5.2482878

74. Peters E, van Elsas A, Heemskerk S, Jonk L, van der Hoeven J, Arend J, et al. Alkaline phosphatase as a treatment of sepsis-associated acute kidney injury. *J Pharmacol Exp Ther* (2013) 344:2–7. doi:10.1124/jpet.112.198226

75. Heemskerk S, Masereeuw R, Moesker O, Bouw MP, van der Hoeven JG, Peters WH, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. *Crit Care Med* (2009) 37:417–423.e1. doi:10.1097/CCM.0b013e31819598af

76. Lukas M, Drastich P, Konecny M, Gionchetti P, Urban O, Cantoni F, et al. Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. *Inflamm Bowel Dis* (2010) 16:1180–6. doi:10.1002/ibd.21161

77. Rader BA, Kremer N, Apicella MA, Goldman WE, McFall-Ngai MJ. Modulation of symbiont lipid a signaling by host alkaline phosphatases in the squid-vibrio symbiosis. *MBio* (2012) 3. doi:10.1128/mBio.00093-12

78. McFall-Ngai M, Hadfield MG, Bosch TCG, Carey HV, Domazet-Lošo T, Douglas AE, et al. Animals in a bacterial world, a new imperative for the life sciences. *Proc Natl Acad Sci U S A* (2013) 110:3229–36. doi:10.1073/pnas.1218525110

79. Robison R, Soames KM. The possible significance of hexosephosphoric esters in ossification. *Biochem J* (1924) 18:740–54. doi:10.1049/ib.00030686-199106000-00001

**Conflict of Interest Statement:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2017 Rader. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*